<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><!--/tmp/3857.pmc.3857/meta_CELL4264.xml--><!--ARTICLE--><?origin publisher?><?FILEmeta_CELL4264 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEmmc1 pdf ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell</journal-id><journal-title>Cell</journal-title><issn pub-type="ppub">0092-8674</issn><issn pub-type="epub">1097-4172</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">CELL4264</article-id><article-id pub-id-type="doi">10.1016/j.cell.2008.11.018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Regulation of PKD by the MAPK p38&#x003b4; in Insulin Secretion and Glucose Homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sumara</surname><given-names>Grzegorz</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">11</xref></contrib><contrib contrib-type="author"><name><surname>Formentini</surname><given-names>Ivan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">11</xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Stephan</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sumara</surname><given-names>Izabela</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Windak</surname><given-names>Renata</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bodenmiller</surname><given-names>Bernd</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Ramracheya</surname><given-names>Reshma</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Caille</surname><given-names>Doroth&#x000e9;e</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Huiping</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Platt</surname><given-names>Kenneth A.</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Meda</surname><given-names>Paolo</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Aebersold</surname><given-names>Rudolf</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Rorsman</surname><given-names>Patrik</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ricci</surname><given-names>Romeo</given-names></name><email>romeo.ricci@cell.biol.ethz.ch</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff10" ref-type="aff">10</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><addr-line><sup>1</sup>Institute of Cell Biology, ETH Zurich, CH-8093 Zurich, Switzerland</addr-line></aff><aff id="aff2"><addr-line><sup>2</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, United Kingdom</addr-line></aff><aff id="aff3"><addr-line><sup>3</sup>Institute of Biochemistry, ETH Zurich, CH-8093 Zurich, Switzerland</addr-line></aff><aff id="aff4"><addr-line><sup>4</sup>Institute of Molecular Systems Biology, ETH Zurich, CH-8093 Zurich, Switzerland</addr-line></aff><aff id="aff5"><addr-line><sup>5</sup>Faculty of Science, University of Zurich, CH-8006 Zurich, Switzerland</addr-line></aff><aff id="aff6"><addr-line><sup>6</sup>Department of Cell Physiology and Metabolism, University of Geneva, CH-1211 Geneva, Switzerland</addr-line></aff><aff id="aff7"><addr-line><sup>7</sup>Department of Biotherapeutics and Integrative Biology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, CT 06877, USA</addr-line></aff><aff id="aff8"><addr-line><sup>8</sup>Lexicon Pharmaceuticals, The Woodlands, Texas, TX 77381, USA</addr-line></aff><aff id="aff9"><addr-line><sup>9</sup>Institute for Systems Physiology, Seattle, WA 98103, USA</addr-line></aff><aff id="aff10"><addr-line><sup>10</sup>Competence Center for Systems Physiology and Metabolic Diseases, CH-8093 Zurich, Switzerland</addr-line></aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>romeo.ricci@cell.biol.ethz.ch</email></corresp><fn id="fn1"><label>11</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="ppub"><day>23</day><month>1</month><year>2009</year></pub-date><volume>136</volume><issue>2</issue><fpage>235</fpage><lpage>248</lpage><history><date date-type="received"><day>29</day><month>4</month><year>2008</year></date><date date-type="rev-recd"><day>22</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; 2009 ELL &#x00026; Excerpta Medica</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p></license></permissions><abstract><title>Summary</title><p>Dysfunction and loss of insulin-producing pancreatic &#x003b2; cells represent hallmarks of diabetes mellitus. Here, we show that mice lacking the mitogen-activated protein kinase (MAPK) <italic>p38&#x003b4;</italic> display improved glucose tolerance due to enhanced insulin secretion from pancreatic &#x003b2; cells. Deletion of <italic>p38&#x003b4;</italic> results in pronounced activation of protein kinase D (PKD), the latter of which we have identified as a pivotal regulator of stimulated insulin exocytosis. p38&#x003b4; catalyzes an inhibitory phosphorylation of PKD1, thereby attenuating stimulated insulin secretion. In addition, <italic>p38&#x003b4;</italic> null mice are protected against high-fat-feeding-induced insulin resistance and oxidative stress-mediated &#x003b2; cell failure. Inhibition of PKD1 reverses enhanced insulin secretion from <italic>p38&#x003b4;</italic>-deficient islets and glucose tolerance in <italic>p38&#x003b4;</italic> null mice as well as their susceptibility to oxidative stress. In conclusion, the p38&#x003b4;-PKD pathway integrates regulation of the insulin secretory capacity and survival of pancreatic &#x003b2; cells, pointing to a pivotal role for this pathway in the development of overt diabetes mellitus.</p></abstract><kwd-group><kwd>SIGNALING</kwd><kwd>CELLBIO</kwd><kwd>HUMDISEASE</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Diabetes results from insufficient (absolute or relative) insulin secretion. In type 1 diabetes, the insulin-producing &#x003b2; cells are destroyed by an autoimmune attack (<xref rid="bib43" ref-type="bibr">von Herrath et&#x000a0;al., 2007</xref>). Type 2 diabetes is often linked to obesity-related insulin resistance, which initially is compensated by enhanced capacity of &#x003b2; cells to secrete insulin. However, in a large subset of obese and insulin-resistant individuals, these compensatory mechanisms are impaired, leading to reduced &#x003b2; cell mass and function and culminating in manifest diabetes (<xref rid="bib22" ref-type="bibr">Kahn et&#x000a0;al., 2006</xref>). &#x003b2; cell damage and insulin resistance appear to be at least partially triggered by inflammatory, oxidative, and endoplasmic reticulum stress-induced pathways including the mitogen-activated protein kinase (MAPK) signaling cascade (<xref rid="bib44" ref-type="bibr">Wellen and Hotamisligil, 2005</xref>). Indeed, activation of the MAPK c-<italic>jun</italic> N-terminal kinase (JNK) represents a central signal transduction event promoting peripheral insulin resistance, suppressing insulin production and secretion, and increasing apoptosis of islet cells (<xref rid="bib19 bib23" ref-type="bibr">Hirosumi et&#x000a0;al., 2002; Kaneto et&#x000a0;al., 2004</xref>).</p><p>The role of the p38 MAPKs (which are closely related to JNK) in these processes remains poorly understood. p38 activity has been reported to be increased in insulin-resistant peripheral tissues from diabetic patients (<xref rid="bib26" ref-type="bibr">Koistinen et&#x000a0;al., 2003</xref>). Moreover, in&#x000a0;vitro data have demonstrated that p38 activation upon exposure to TNF-&#x003b1;, free fatty acids, and oxidative stress impairs insulin signaling in adipocytes and skeletal muscle cells through mechanisms very similar to those described for JNK (<xref rid="bib9" ref-type="bibr">de Alvaro et&#x000a0;al., 2004</xref>). Finally, activation of p38 appears to trigger pancreatic &#x003b2; cell dysfunction and apoptosis in response to oxidative stress and cytokines in&#x000a0;vitro (<xref rid="bib31" ref-type="bibr">Makeeva et&#x000a0;al., 2006</xref>). Verification of an involvement of p38 in metabolic diseases in&#x000a0;vivo is complicated by the existence of four different <italic>p38</italic> genes, <italic>p38&#x003b1;</italic>, <italic>p38&#x003b2;</italic>, <italic>p38&#x003b3;</italic>, and <italic>p38&#x003b4;</italic>.</p><p>To date, the best-characterized p38 isoform is p38&#x003b1;. It has been shown that <italic>p38&#x003b1;</italic> knockout mice die at midgestation, likely because of a defective placental organogenesis (<xref rid="bib1 bib32 bib39" ref-type="bibr">Adams et&#x000a0;al., 2000; Mudgett et&#x000a0;al., 2000; Tamura et&#x000a0;al., 2000</xref>). Recently, it has been demonstrated that p38&#x003b1; is a fundamental regulator of cellular proliferation and carcinogenesis in&#x000a0;vivo (<xref rid="bib20 bib41" ref-type="bibr">Hui et&#x000a0;al., 2007; Ventura et&#x000a0;al., 2007</xref>). p38&#x003b1; is also required to mediate an inflammatory response in macrophages (<xref rid="bib24" ref-type="bibr">Kang et&#x000a0;al., 2008</xref>). On the basis of inhibitor studies, it was postulated that p38&#x003b1; and p38&#x003b2; functionally cooperate in the context of inflammatory processes. However, <italic>p38&#x003b2;</italic>-specific knockout mice revealed no differences in several in&#x000a0;vivo and in&#x000a0;vitro models of inflammation (<xref rid="bib6" ref-type="bibr">Beardmore et&#x000a0;al., 2005</xref>).</p><p>The least-characterized isoforms are p38&#x003b3; and p38&#x003b4;. p38&#x003b3; is predominantly expressed in skeletal muscle and heart, and <italic>p38&#x003b3;</italic>-deficient myoblasts exhibited an attenuated cell-to-cell fusion capacity in&#x000a0;vitro (<xref rid="bib36" ref-type="bibr">Perdiguero et&#x000a0;al., 2007</xref>). The isoform p38&#x003b4; shares approximately 60% homology with the other p38 family members and about 40% homology with other MAPKs. Like p38&#x003b1;, p38&#x003b4; is activated by various stress stimuli, including inflammatory cytokines and oxidative stress (<xref rid="bib21" ref-type="bibr">Jiang et&#x000a0;al., 1997</xref>). Recent in&#x000a0;vitro studies have demonstrated that p38&#x003b4; might be involved in keratinocyte differentiation and PKC&#x003b4;-dependent keratinocyte apoptosis (<xref rid="bib12" ref-type="bibr">Efimova et&#x000a0;al., 2004</xref>), as well as the progression of neurodegenerative disorders referred to as tauopathies (<xref rid="bib13" ref-type="bibr">Feijoo et&#x000a0;al., 2005</xref>). However, no specific in&#x000a0;vivo functions of p38&#x003b4; have been reported thus far.</p><p>To address such functions, we generated <italic>p38&#x003b4;</italic> null mice. Remarkably, these mice displayed improved glucose tolerance due to enhanced insulin exocytosis from pancreatic &#x003b2; cells. Moreover, inactivation of <italic>p38&#x003b4;</italic> protected against hyperlipidemia-induced insulin resistance and oxidative stress-imposed &#x003b2; cell apoptosis. At the molecular level, we discovered that p38&#x003b4; exerts an inhibitory phosphorylation on protein kinase D 1 (PKD1), a kinase that regulates both stimulated insulin secretion and pancreatic &#x003b2; cell survival. We propose that p38&#x003b4; represents a critical regulator of glucose homeostasis in&#x000a0;vivo.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Enhanced Glucose Tolerance in <italic>p38&#x003b4;</italic> Null Mice Due to Increased Insulin Exocytosis from Pancreatic &#x003b2; Cells</title><p>To address in&#x000a0;vivo functions of p38&#x003b4; in metabolism, we generated <italic>p38&#x003b4;</italic> floxed mice and crossed them with <italic>protamine</italic> promoter-driven Cre recombinase-expressing mice, a male germline deleter strain (<xref rid="bib34" ref-type="bibr">O'Gorman et&#x000a0;al., 1997</xref>). With this approach, we obtained <italic>p38&#x003b4;</italic> null mice (<italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice) and corresponding wild-type control littermates (<italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice) (<xref rid="app2" ref-type="sec">Figure&#x000a0;S1</xref> available online). <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice presented with normal general health, viability, fecundity, body composition, and body weight (data not shown). Assessment of the expression of p38&#x003b4; in organs involved in glucose homeostasis revealed that p38&#x003b4; was abundantly expressed both at the mRNA and protein level and in similar amounts in the exo- and endocrine pancreas. In contrast, no expression of p38&#x003b4; was observed in insulin-sensing organs such as adipose tissue and liver. Very low amounts of <italic>p38&#x003b4;</italic> mRNA were detected in skeletal muscle (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A and <xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>A).</p><p>The observed expression pattern prompted us to investigate the role of p38&#x003b4; in glucose homeostasis. <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice fasted for 16 hr showed a significantly enhanced glucose tolerance compared to <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B), while insulin sensitivity was equal in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>B). Although lower glucose levels were attained in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice after the glucose challenge, circulating insulin levels were increased compared to <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> control mice. The glucose challenge elicited a biphasic insulin response; both initial first phase and subsequent second phase were enhanced in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C).</p><p>Enhanced insulin release in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> mice was not the consequence of alterations in the &#x003b2; cell mass, in the pancreatic islet architecture, or in insulin content (<xref rid="app2" ref-type="sec">Figure&#x000a0;S3</xref>). Transmission electron microscopy further revealed that the volume density and distribution of both pale (immature) and dense core (mature) secretory granules were similar in &#x003b2; cells in islets of <italic>p38&#x003b4;<sup>&#x0002b;/&#x0002b;</sup></italic> and <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> mice (<xref rid="app2" ref-type="sec">Table S1</xref>).</p><p>To test whether enhanced insulin secretion in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> mice primarily reflects an intrinsic islet/&#x003b2; cell effect that is independent of the action of incretins or innervation, we isolated pancreatic islets from <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice and tested their capacity to secrete insulin in&#x000a0;vitro. Knockout islets released more insulin both under basal (2.8 mM glucose) and glucose-stimulated (16.7 mM glucose) conditions compared to control islets (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). By contrast, glucagon secretion was unaffected in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> islets, and high glucose (16.7 mM) inhibited the release of the hormone to the same extent in both wild-type and knockout islets (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E). These data suggest that lack of <italic>p38&#x003b4;</italic> improves glucose tolerance and enhances insulin secretion by a direct and &#x003b2; cell-specific mechanism.</p></sec><sec id="sec2.2"><title>Enhanced Insulin Exocytosis in <italic>p38&#x003b4;</italic>-Deficient Pancreatic &#x003b2; Cells Is Independent of Differences in Glucose Metabolism, K<sub>ATP</sub> Closure, and Ca<sup>2&#x0002b;</sup> Influx</title><p>We next addressed at which step p38&#x003b4; interferes with the insulin secretory pathway in pancreatic &#x003b2; cells. In <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> islets, insulin secretion elicited by either 20 mM KCl (to evoke depolarization of membrane) or 100 &#x003bc;M tolbutamide (to close ATP-regulated K<sup>&#x0002b;</sup> channels and elicit electrical activity) was enhanced compared to control islets (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D).</p><p>To determine whether ablation of <italic>p38&#x003b4;</italic> affects Ca<sup>2&#x0002b;</sup> influx, we measured intracellular calcium concentrations ([Ca<sup>2&#x0002b;</sup>]<sub>i</sub>) in response to glucose and KCl in islets isolated from <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice. The average [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> was similar in the two groups of islets both under basal conditions (2.8 mM glucose) and after stimulation by either glucose (16.7 mM) or KCl (20&#x000a0;mM in the presence of 2.8 mM glucose) (<xref rid="app2" ref-type="sec">Figures S4</xref>A and S4B). Likewise, whole-cell Ca<sup>2&#x0002b;</sup> currents were comparable in single &#x003b2; cells of <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> littermates (<xref rid="app2" ref-type="sec">Figures S4</xref>C and S4D). The fact that insulin secretion was enhanced in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> islets despite similar [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> levels suggests that p38&#x003b4; acts directly at the level of exocytosis.</p><p>To address whether exocytosis is enhanced in <italic>p38&#x003b4;</italic>-deficient &#x003b2; cells, we performed high-resolution capacitance measurements of exocytosis on single &#x003b2; cells (<xref rid="bib17" ref-type="bibr">Gopel et&#x000a0;al., 2004</xref>). A train of ten depolarization steps from &#x02212;70 mV to 0 mV evoked larger responses in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> than in control &#x003b2; cells, resulting in a 2-fold larger increase of membrane capacitance in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>A and 2B). Exocytosis was enhanced approximately equally in <italic>p38&#x003b4;&#x00394;/&#x00394;</italic> compared to <italic>p38&#x003b4;</italic>&#x0002b;/&#x0002b; &#x003b2; cells throughout the trains of depolarization. The rate of capacitance increase in cells lacking <italic>p38&#x003b4;</italic> was also higher than that of wild-type cells when exocytosis was elicited by clamping [Ca<sup>2&#x0002b;</sup>] at 1.5 &#x003bc;M, a condition that bypasses any effects on Ca<sup>2&#x0002b;</sup> entry (<xref rid="fig2" ref-type="fig">Figures 2</xref>C and 2D). Collectively, these results indicate that the enhanced insulin secretion from <italic>p38&#x003b4;</italic>-deficient islets is not caused by differences in glucose metabolism, K<sub>ATP</sub> closure, or [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> homeostasis between knockout and control &#x003b2; cells. Rather, ablation of p38&#x003b4; influences insulin secretion by a direct effect on the exocytotic machinery that is exerted downstream of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> elevation.</p></sec><sec id="sec2.3"><title>p38&#x003b4; Exerts an Inhibitory Phosphorylation on Protein Kinase D 1</title><p>We next investigated a possible molecular mechanism by which p38&#x003b4; attenuates insulin exocytosis using an unbiased proteomic approach. We ectopically expressed a hemagglutinin (HA)-tagged constitutively active form of p38&#x003b4;, obtained by substitution of phenylalanine 324 with serine (F324S) as previously described (<xref rid="bib3" ref-type="bibr">Askari et&#x000a0;al., 2007</xref>), in 293T cells. Constitutive activity was tested in an in&#x000a0;vitro kinase assay using recombinant HIS-tagged ATF-2 as a substrate (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>A). HA immunoprecipitates from HA-p38&#x003b4;<sup>F324S</sup> and HA-expressing cells were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A number of putative interactors were obtained among which protein kinase D 1 (PKD1) was most frequently found (represented by a total of 36 unique peptides) (<xref rid="app2" ref-type="sec">Table S2</xref>). PKD is necessary for biogenesis of trans-Golgi network (TGN) to cell surface transport carriers (<xref rid="bib5" ref-type="bibr">Bard and Malhotra, 2006</xref>) and has been shown to be a positive regulator of secretion in neuroendocrine cells (<xref rid="bib29" ref-type="bibr">Li et&#x000a0;al., 2004</xref>). The interaction between p38&#x003b4; and PKD1 was confirmed by coimmunoprecipitation experiments in 293T cells (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>B). HA pulldowns also contained endogenous PKD1 in INS1 cells (rat insulinoma-derived pancreatic &#x003b2; cell line) stably expressing HA-p38&#x003b4;<sup>F324S</sup> but not in cells expressing HA alone (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A).</p><p>We then tested the ability of p38&#x003b4; to directly phosphorylate PKD1 in&#x000a0;vitro. Active recombinant p38&#x003b4; phosphorylated immunoprecipitated human GFP-tagged wild-type PKD1 (GFP-PKD1-WT) and kinase-dead PKD1 (GFP-PKD1-KD) (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>C), as well as Sf9 cell-derived (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>D) and <italic>E. coli</italic>-expressed recombinant human GST-PKD1 (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). Bacterial PKD1 showed high basal activity that caused high autophosphorylation. However, enhancement of phosphorylation by addition of p38&#x003b4; became more evident when the PKD inhibitor G&#x000f6;6976 was added to the reactions to reduce autophosphorylation. The LC-MS/MS analysis of in&#x000a0;vitro phosphorylated immunoprecipitated murine GST-PKD1 identified an autophosphorylation and a 14-3-3 binding site (Ser<sup>203</sup> and Ser<sup>206</sup>) (<xref rid="bib46" ref-type="bibr">Zhang et&#x000a0;al., 2005</xref>), one of the activating dual phosphorylation sites (Ser<sup>748</sup>), and a protein kinase C-dependent transphosporylation site (Ser<sup>255</sup>) (<xref rid="bib42" ref-type="bibr">Vertommen et&#x000a0;al., 2000</xref>) (<xref rid="app2" ref-type="sec">Figure&#x000a0;S6</xref>). p38&#x003b4; specifically phosphorylated Ser<sup>403</sup>, a p38 MAPK consensus site (SP/TP), as well as the closely located Ser<sup>407</sup> residue (<xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>). LC-MS/MS analysis of the HA-p38&#x003b4;<sup>F324S</sup> immunoprecipitates from 293T cells confirmed Ser<sup>403</sup> phosphorylation on endogenous PKD (data not shown). Both phosphorylation sites are conserved between mouse (Ser<sup>403</sup> and Ser<sup>407</sup>), rat, and human (Ser<sup>397</sup> and Ser<sup>401</sup>) and can be found in PKD1 and PKD3 but not in PKD2 (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). PKD1 is the predominant isoform expressed in pancreatic &#x003b2; cells (data not shown).</p><p>We next generated the corresponding single and double serine to alanine mutants of kinase-dead PKD1 and double serine to alanine mutants of wild-type PKD1 (GFP-PKD1-AA), as well as double serine to aspartate mutants of wild-type PKD1 (GFP-PKD1-DD). Mutations of either Ser<sup>397</sup> or Ser<sup>401</sup> to alanines significantly reduced p38&#x003b4;-dependent phosphorylation in&#x000a0;vitro, and mutation of both sites diminished autoradiography almost to background levels (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D). The ability of kinases to phosphorylate the substrate CREBtide was assayed in&#x000a0;vitro. Autoradiography of spotted CREBtide from reactions with GFP-PKD1-KD was markedly reduced compared to reactions with GFP-PKD1-WT, while no signal could be detected with CREBtide from reactions with GFP only. Importantly, CREBtide autoradiography from reactions containing GFP-PKD1-AA was enhanced, whereas it was markedly reduced in reactions with GFP-PKD1-DD compared to reactions with GFP-PKD1-WT. Quantification of radiography of purified CREBtide with a scintillation counter confirmed respective kinase activities (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E). These results suggest that PKD1 is a direct substrate of p38&#x003b4; and that p38&#x003b4;-dependent phosphorylation of PKD1 constitutes an inhibitory modification.</p></sec><sec id="sec2.4"><title>Enhanced Activity of PKD and Altered Golgi Organization in Pancreatic &#x003b2; Cells Lacking p38&#x003b4;</title><p>We proceeded to test whether lack of <italic>p38&#x003b4;</italic> results in increased activity of PKD in pancreas by assessing PKD autophosphorylation (serine 916). The activity was markedly enhanced in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> compared to <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> pancreas (<xref rid="app2" ref-type="sec">Figure&#x000a0;S8</xref>). To confirm increased PKD activity in &#x003b2; cells, we generated MIN6 cells (murine insulinoma-derived pancreatic &#x003b2; cell line) stably expressing small hairpins (shRNA) against <italic>p38&#x003b4;</italic>. Consistently, lack of <italic>p38&#x003b4;</italic> enhanced insulin secretion also in MIN6 cells (see below). Indeed, a marked increase in activatory PKD phosphorylation was also observed in MIN6 cells lacking <italic>p38&#x003b4;</italic> compared to control cells, which was further increased in <italic>p38&#x003b4;</italic>-deficient cells stimulated by glucose (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A).</p><p>Activation of PKD induces membrane fission at the TGN, which can be monitored by altered localization of Golgi marker proteins by immunofluorescence (<xref rid="bib8 bib30" ref-type="bibr">Bossard et&#x000a0;al., 2007; Liljedahl et&#x000a0;al., 2001</xref>). Indeed, the Golgi markers giantin, furin convertase, and GM130 exhibited a diffuse distribution in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> primary pancreatic &#x003b2; cells, whereas a characteristic crescent-shaped staining was found in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B and <xref rid="app2" ref-type="sec">Figure&#x000a0;S9</xref>). Altered Golgi organization was confirmed in MIN6 cells lacking <italic>p38&#x003b4;</italic> by immunofluorescence stainings of giantin (<xref rid="app2" ref-type="sec">Figure&#x000a0;S10</xref>). Conversely, INS1 cells ectopically expressing HA-p38&#x003b4;<sup>F324S</sup> showed tubular protrusions from the Golgi apparatus reminiscent of inhibited TGN membrane fission (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). The latter cellular phenotype correlated with suppressed stimulated insulin secretion in INS1 cells (see below). Collectively, these data indicate that lack of <italic>p38&#x003b4;</italic> leads to constitutive PKD activity and enhanced membrane fission at the TGN in pancreatic &#x003b2; cells, whereas increased p38&#x003b4; activity has the opposite effects.</p></sec><sec id="sec2.5"><title>Inhibitors of Phospolipase C and Conventional PKCs Restore Insulin Secretion in <italic>p38&#x003b4;</italic>-Deficient Islets</title><p>Generation of diacylglycerol (DAG) by phosphatidyl-inositol-specific phospholipases C (PI-PLCs; PLC, phospolipase C) activates PKD, which is subsequently recruited to the TGN, where it promotes membrane fission (<xref rid="bib10" ref-type="bibr">Diaz Anel, 2007</xref>). Pharmacological inhibition of this pathway is expected to reverse cellular phenotypes and related effects caused by deletion of <italic>p38&#x003b4;</italic>. To test this, we used the PI-PLC inhibitor U73122 and G&#x000f6;6976, a potent inhibitor of PKD and conventional protein kinases C (PKCs) (<xref rid="bib18" ref-type="bibr">Haxhinasto and Bishop, 2003</xref>). Both U73122 and G&#x000f6;6976 resulted in relocalization of giantin to the TGN in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> pancreatic &#x003b2; cells, whereas none of the compounds altered normal localization of giantin in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> cells (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). These cellular effects echoed those on glucose-evoked (16.7&#x000a0;mM) insulin secretion: none of the compounds had any effect on insulin secretion from <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> islets, but the enhancement seen in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> islets was abolished (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). Importantly, peritoneal injections of U73122 decreased glucose tolerance of <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice to that observed in dimethyl sulfoxide (DMSO)-treated <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> controls, without modifying glucose tolerance of the control animals (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). Thus, inhibition of PKD reverses the effects of <italic>p38&#x003b4;</italic> ablation on Golgi organization, insulin secretion, and glucose tolerance.</p></sec><sec id="sec2.6"><title>p38&#x003b4; Negatively Regulates PKD-Mediated Stimulated Insulin Secretion</title><p>PKD resides in the G<sub>q</sub> protein-coupled receptor (G<sub>q</sub>PCR) pathway, which in &#x003b2; cells is known to be strongly activated by the insulin secretagogue acetylcholine (<xref rid="bib16" ref-type="bibr">Gilon and Henquin, 2001</xref>). Indeed, activity of PKD was markedly increased upon stimulation with the acetylcholine analog carbachol. By contrast, exendin-4 (a GLP-1 analog) (<xref rid="bib11" ref-type="bibr">Drucker, 2006</xref>), forskolin (<xref rid="bib45" ref-type="bibr">Wiedenkeller and Sharp, 1983</xref>), and glucose did not detectably activate PKD (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). The activity of p38&#x003b4; in response to carbachol was examined in INS1 cells with the Phos-tag technology (<xref rid="bib25" ref-type="bibr">Kinoshita et&#x000a0;al., 2006</xref>). Both phosphorylated p38&#x003b4; and nonphosphorylated p38&#x003b4; declined in INS1 cells (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), indicating that&#x000a0;carbachol-induced activation of PKD1 correlates with p38&#x003b4; inhibition.</p><p>We next assessed the role of PKD1 in insulin secretion. PKD1 was specifically inactivated in INS1 cells by siRNA-mediated knockdown with two independent oligonucleotide sequences as compared to a scrambled control siRNA (<xref rid="app2" ref-type="sec">Figure&#x000a0;S11</xref>A). Although an induction of PKD activity was only apparent upon stimulation with carbachol, deletion of PKD1 in INS1 cells completely blocked insulin secretion in response to both carbachol and glucose (<xref rid="app2" ref-type="sec">Figure&#x000a0;S11</xref>B), indicating a general requirement of PKD1 in stimulated insulin secretion. We went on to investigate whether PKD activity and insulin secretion in response to glucose and carbachol is p38&#x003b4; dependent. Carbachol-stimulated activation of PKD was markedly reduced in INS1 cells expressing HA-p38&#x003b4;<sup>F324S</sup> compared to cells expressing HA alone (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C). Importantly, expression of HA-p38&#x003b4;<sup>F324S</sup> in INS1 cells completely blocked insulin secretion in response to carbachol and also attenuated secretion in response to glucose (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>D).</p><p>We subsequently tested whether inactivation of PKD1 reverses insulin release in the absence of <italic>p38&#x003b4;</italic> to levels seen in wild-type cells. For this purpose, we used MIN6 cells stably expressing shRNA against <italic>p38&#x003b4;</italic> as well as control cells expressing an empty vector and simultaneously performed siRNA against PKD1. Efficient knockdown of p38&#x003b4; and PKD1 was confirmed by Western blotting (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A and <xref rid="app2" ref-type="sec">Figure&#x000a0;S12</xref>A). Compared to control cells, MIN6 cells lacking <italic>p38&#x003b4;</italic> showed enhanced insulin secretion in the presence of basal (2.8 mM) and of stimulatory glucose levels (25 mM), whereas knockdown of <italic>Pkd1</italic>, as seen in INS1 cells (<xref rid="app2" ref-type="sec">Figure&#x000a0;S11</xref>), led to blockage of glucose-stimulated insulin secretion. Inactivation of <italic>Pkd1</italic> in MIN6 cells lacking <italic>p38&#x003b4;</italic> lowered insulin secretion to levels observed in control MIN6 cells (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>E).</p><p>Finally, to assess the functional relevance of p38&#x003b4;-dependent PKD1 phosphorylation, we generated INS1 cells ectopically expressing mutated forms of PKD1 (<xref rid="app2" ref-type="sec">Figure&#x000a0;S12</xref>B). Importantly, glucose-induced insulin secretion was suppressed by expression of GFP-PKD1-DD under stimulatory glucose conditions, whereas it was markedly increased by expression of GFP-PKD1-AA under both basal and stimulatory glucose conditions compared to GFP- and GFP-PKD1-WT-expressing cells (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>F). Altogether, these data suggest that p38&#x003b4; suppresses PKD-mediated stimulated insulin secretion.</p></sec><sec id="sec2.7"><title><italic>p38&#x003b4;</italic> Deficiency Protects against Insulin Resistance and Pancreatic &#x003b2; Cell Failure</title><p>To challenge the insulin secretion capacity of islets, we placed <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice on a high-fat diet, a widely used model for insulin resistance (<xref rid="bib7" ref-type="bibr">Biddinger and Kahn, 2006</xref>). Although insulin sensitivity was reduced by this protocol in both genotypes, it remained significantly better in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> compared to <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<xref rid="app2" ref-type="sec">Figure&#x000a0;S13</xref>A). Improved insulin sensitivity in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice was associated with a moderately reduced body weight gain (<xref rid="app2" ref-type="sec">Figure&#x000a0;S13</xref>B). As expected, insulin resistance led to a marked hyperinsulinemia in both <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice compared to mice on a normal diet. However, <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice showed significantly enhanced fasting insulin levels on a high-fat diet compared to <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice, indicating that they maintain their enhanced capacity to secrete insulin also under insulin-resistant conditions (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>A). No significant differences in islet growth in <italic>p38</italic>&#x003b4;<italic><sup>&#x0002b;/&#x0002b;</sup></italic> and <italic>p38</italic>&#x003b4;<sup>&#x00394;/&#x00394;</sup> mice in response to a high-fat diet could be observed (<xref rid="app2" ref-type="sec">Figure&#x000a0;S14</xref>).</p><p>Overall, differences in insulin sensitivity as well as insulin levels resulted in a significantly improved glucose tolerance in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice on a high-fat diet (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>B). Thus, lack of <italic>p38&#x003b4;</italic> provides protection against lipid-induced glucose intolerance.</p><p>Oxidative stress is known to contribute to pancreatic &#x003b2; cell loss in insulin resistance-related diabetes mellitus (<xref rid="bib14" ref-type="bibr">Fridlyand and Philipson, 2006</xref>). Streptozotocin (STZ)-induced oxidative stress is a widely used model to trigger pancreatic &#x003b2; cell failure in&#x000a0;vivo (<xref rid="bib27" ref-type="bibr">Le May et&#x000a0;al., 2006</xref>). We confirmed that STZ activates p38&#x003b4; in pancreatic &#x003b2; cells (<xref rid="app2" ref-type="sec">Figure&#x000a0;S15</xref>A). As expected, glucose levels increased in <italic>p38&#x003b4;<sup>&#x0002b;/&#x0002b;</sup></italic> mice after STZ injection, reaching up to 15 mmol/l concentrations at day 8. However, no such increase was observed in <italic>p38&#x003b4;<sup>&#x00394;/&#x00394;</sup></italic> mice, in which plasma glucose levels remained stable and around 7 mmol/l throughout the observation period (<xref rid="app2" ref-type="sec">Figure&#x000a0;S15</xref>B). Plasma insulin levels and pancreatic insulin content were significantly higher in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice than in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice treated with STZ (<xref rid="app2" ref-type="sec">Figures S15</xref>C and S15D). The involvement of PKD in the protection of &#x003b2; cells in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice was tested with the inhibitor U73122. In <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice, U73122 increased plasma glucose and lowered insulin to the same levels as in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice after STZ injections (<xref rid="fig7" ref-type="fig">Figures 7</xref>C&#x02013;7E). The inhibitor had no additive effect in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice.</p><p>TUNEL staining revealed that whereas STZ-induced hyperglycemia in <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> mice was associated with a high rate of &#x003b2; cell apoptosis, the rate of apoptosis was 5-fold lower in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> mice. The protective effect of lack of <italic>p38&#x003b4;</italic> on apoptosis was abolished by U73122 (<xref rid="fig7" ref-type="fig">Figures 7</xref>F and 7G). These data raise the interesting possibility that p38&#x003b4;-imposed inhibition of PKD might contribute to &#x003b2; cell dysfunction and destruction in diabetic subjects.</p></sec></sec><sec id="sec3"><title>Discussion</title><p>A nonredundant and specific in&#x000a0;vivo function of the &#x003b4; isoform of the MAPK family p38 has not been elucidated so far. We now provide compelling evidence that p38&#x003b4; represents a key regulator of pancreatic &#x003b2; cell function. Our work supports a negative regulatory role for p38&#x003b4; in stimulated insulin secretion through inhibition of PKD1 and regulation of exocytosis. Moreover, immoderate suppression of PKD activity by p38&#x003b4; may also contribute to &#x003b2; cell dysfunction in diabetic subjects.</p><sec id="sec3.1"><title>The p38&#x003b4;-PKD1 Pathway Regulates Stimulated Insulin Secretion from Pancreatic &#x003b2; Cells</title><p>We demonstrate that ablation of <italic>p38&#x003b4;</italic> activates PKD1, and thereby enhances insulin secretion and consequently improves glucose tolerance. Furthermore, we show that the acetylcholine analog carbachol strongly activates PKD in pancreatic &#x003b2; cells. This physiological function of PKD1 can be completely blocked by enhancement of p38&#x003b4; activity. Acetylcholine represents the major neurotransmitter of the peripheral parasympathetic nervous system, and its binding on muscarinic acetylcholine receptors located on the pancreatic &#x003b2; cells potentiates secretion of insulin (<xref rid="bib15" ref-type="bibr">Gautam et&#x000a0;al., 2006</xref>). Indeed, muscarinic receptors belong to G<sub>q</sub> protein-coupled receptors stimulating PLC to produce inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and DAG, the latter of which activates numerous PKC family members, including PKD (<xref rid="bib35" ref-type="bibr">Oancea et&#x000a0;al., 2003</xref>) (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>H).</p><p>Importantly, PKD1 deletion also blocks insulin secretion in response to glucose. PKD activity upon glucose stimulation could not be detected in wild-type &#x003b2; cells. However, in &#x003b2; cells lacking <italic>p38&#x003b4;</italic>, in which PKD activity is constitutively enhanced, a 2-fold increase of PKD activity was seen upon glucose stimulation (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). It has been reported that glucose generates DAG in &#x003b2; cells (<xref rid="bib37" ref-type="bibr">Peter-Riesch et&#x000a0;al., 1988</xref>). This can either occur by a direct effect of glucose metabolism or be secondary to glucose-induced increases in [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>- and Ca<sup>2&#x0002b;</sup>-induced activation of PLC (<xref rid="bib40" ref-type="bibr">Thore et&#x000a0;al., 2007</xref>) (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>H). It is therefore tempting to speculate that activity of PKD is also rising in response to glucose in wild-type cells but is probably below our detection limit. Altogether, our data support a key role of the p38&#x003b4;-PKD1 pathway in stimulated insulin secretion.</p></sec><sec id="sec3.2"><title>The p38&#x003b4;-PKD1 Pathway Regulates Proximal and Distal Steps of Exocytosis in Pancreatic &#x003b2; Cells</title><p>The findings in capacitance experiments conform to functions of the herein identified p38&#x003b4; target, PKD1. One of the most established roles of PKD is to promote fission of cell surface-destined transport carriers from the TGN (<xref rid="bib8 bib30" ref-type="bibr">Bossard et&#x000a0;al., 2007; Liljedahl et&#x000a0;al., 2001</xref>). Enhanced membrane fission at the TGN in the&#x000a0;absence of <italic>p38&#x003b4;</italic> most likely accounts for late effects (pulses 5 to 10) seen in capacitance experiments.</p><p>Importantly, it has been demonstrated that ectopic expression of constitutively active PKD is sufficient to promote secretion of neurotensin, implying that PKD in addition to its function at the TGN primes vesicles for efficient transport and immediate fusion (<xref rid="bib29" ref-type="bibr">Li et&#x000a0;al., 2004</xref>). Accordingly, enhanced PKD activity might also explain early effects (pulses 1 to 4) observed in capacitance experiments. Indeed, a very recent report suggests that PKD-mediated secretion of neurotensin requires its target, Kidins220, the latter of which is proposed to regulate more distal steps of exocytosis (<xref rid="bib28" ref-type="bibr">Li et&#x000a0;al., 2008</xref>). Moreover, although not specifically reported for PKD so far, PKCs downstream of DAG were shown to increase the efficiency of Ca<sup>2&#x0002b;</sup> on insulin exocytosis independent of a rise in cytosolic free Ca<sup>2&#x0002b;</sup> levels, a mechanism that also underlies acetylcholine-mediated insulin secretion (<xref rid="bib16" ref-type="bibr">Gilon and Henquin, 2001</xref>). The observed increase of exocytosis is also reminiscent of that previously reported for the PKC/PKD activator PMA, the latter effect also being exerted distally to the elevation of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> (<xref rid="bib2" ref-type="bibr">Ammala et&#x000a0;al., 1994</xref>).</p><p>Overall, our data indicate that stimulated insulin secretion is increased, at least partially, through enhancement of the efficiency of TGN function, a cellular mechanism, which has not been reported so far in this context.</p></sec><sec id="sec3.3"><title>The p38&#x003b4;-PKD1 Axis Might be Pivotal in Maintaining &#x003b2; Cell Function in Diabetic Conditions</title><p>In our study, we have challenged the secretory capacity of pancreatic islets in knockout mice with a high-fat diet, which induces peripheral insulin resistance, leading to adaptive hyperinsulinemia. Interestingly, <italic>p38&#x003b4;</italic> null mice developed less severe insulin resistance. Strikingly, <italic>p38&#x003b4;</italic> null mice on a high-fat diet became hyperinsulinemic, reaching fasting insulin levels that were significantly higher than those in high fat-fed control mice. The relative importance of increased insulin sensitivity and enhanced insulin secretion to the overall improved glucose tolerance needs to be further investigated in the future.</p><p>Additionally, we have shown that p38&#x003b4; plays yet another key function in the &#x003b2; cell: the regulation of &#x003b2; cell destruction during oxidative stress, which is a key pathogenic mechnism in both, type 1 and type 2 diabetes mellitus (<xref rid="bib33" ref-type="bibr">Muoio and Newgard, 2008</xref>). Strikingly, <italic>p38&#x003b4;</italic> knockout mice were protected against STZ-imposed oxidative stress in &#x003b2; cells. Importantly, this phenotype also appears to be dependent on PKD activity. This is in agreement with the report demonstrating that PKD activation is protective against oxidative stress-induced apoptosis through activation of NF-&#x003ba;B (<xref rid="bib38" ref-type="bibr">Storz and Toker, 2003</xref>). Even though p38&#x003b4; fine-tunes PKD-mediated insulin secretion in normal physiologic settings, in pathological situations of gradually increasing cellular oxidative stress, p38&#x003b4; activity might exceed and PKD activity may drop to levels affecting insulin secretion as well as &#x003b2; cell survival (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>H).</p><p>There is accumulating evidence that forcing &#x003b2; cells to secrete insulin by currently used drugs, including sulfonylureas, ultimately results in pancreatic &#x003b2; cell failure (<xref rid="bib4" ref-type="bibr">Aston-Mourney et&#x000a0;al., 2008</xref>). An ideal pharmacological diabetes therapy should therefore combine an insulinotropic effect with protection against &#x003b2; cell failure. Our data suggest that pharmacological suppression of p38&#x003b4; might represent such an approach. Conclusively, the p38&#x003b4;-PKD pathway modulates both insulin secretion and &#x003b2; cell turnover and thus provides a unifying mechanism that integrates these two pathogenic features of human diabetes.</p></sec></sec><sec sec-type="materials-methods" id="sec4"><title>Experimental Procedures</title><sec id="sec4.1"><title>Generation of Mice</title><p>The <italic>p38&#x003b4;</italic> floxed mice were generated at Lexicon Pharmaceuticals (The Woodlands, TX) (for details, see the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>). For generation of p38&#x003b4; null mice, a targeting vector harboring LoxP sites within the 5&#x02032; UTR region and intron 1-2 (floxed exon 1) as well as a neomycin resistance cassette flanked by two FRT sites were electroporated into 129/SvEv<sup>Brd</sup> (Lex-1) ES cells. Targeted ES cell clones were microinjected into C57BL/6 (albino) blastocysts to generate chimeric animals, which were bred to C57BL/6 (albino) females, and the resulting heterozygous offspring were bred with a protamine-Cre recombinase transgenic line to delete exon 1. Mice heterozygous for exon 1 deletion were backcrossed five times to the C57BL/6 background and intercrossed to generate homozygous knockout mice. All procedures involving animals were approved by the Veterin&#x000e4;ramt des Kantons Z&#x000fc;rich and conform to the relevant regulatory standards.</p></sec><sec id="sec4.2"><title>Mouse Experiments</title><p>For the glucose tolerance test, 8-week-old male mice were fasted for 16 hr and then injected intraperitoneally (i.p.) with glucose (2 g/kg body weight [bw]). Glucose was measured with the Accu-Chek Aviva system from Roche. In experiments with the PI-PLC inhibitor U73122 (Sigma), mice were injected i.p. with U73122 (2.5 mg/kg bw) in DMSO or with DMSO 1 hr prior experiment. Insulin tolerance tests were performed on 8-week-old ad libitum-fed male mice injected i.p. with insulin (1 U/kg bw). Plasma insulin levels were measured with an insulin RIA kit (Linco). STZ (150 mg/kg bw) was injected once i.p., and blood glucose was measured each day. After 8 days, mice were sacrificed, serum was harvested, and the pancreas was isolated to measure insulin serum levels and insulin content, respectively. In STZ experiments with U73122, mice were injected i.p. with U73122 (2.5 mg/kg bw) in DMSO or with DMSO only, three times (day 1, 2, and 3) after STZ injection. Peripheral insulin resistance was induced by feeding of mice for 12 weeks with a high-fat diet (Research Diets, D12331). After this period, mice were subjected to insulin tolerance tests (1 U/kg bw) as well as glucose tolerance tests (1 g/kg bw).</p></sec><sec id="sec4.3"><title>Islets Isolation and Insulin Secretion</title><p>Islets were isolated by collagenase perfusion (1.9 U/ml) of pancreas and subsequent digestion for 16 min at 37&#x000b0;C. Islets were handpicked and transferred to RPMI1640 media containing 5 mM glucose and maintained for 3 hr prior to the experiments or dispersed in calcium-free solution and then cultured as above. For static incubations, islets were subsequently preincubated for 60 min at 37&#x000b0;C in Krebs-Ringer bicarbonate buffer (pH 7.4), supplemented with 0.05% bovine serum albumin (BSA) and 2.8 mM glucose. After preincubation, the supernatant was discarded and the islets were incubated in buffer solution containing 2.8 or 16.7 mM glucose for 60 min at 37&#x000b0;C. For the rescue experiments, islets were incubated as described above but in presence of 10 &#x003bc;M of U73122 or 1 &#x003bc;M G&#x000f6;6976 or DMSO. The islets were resuspended in acid ethanol and frozen for insulin content measurements. Insulin secretion data were expressed as percentage of pellet. Insulin secretion from INS1 and MIN6 cells was performed as described for islets, and data were normalized to nonstimulated control cells. Total insulin from pancreas was isolated by acid-ethanol extraction. Insulin content was normalized to the total weight of the pancreas.</p></sec><sec id="sec4.4"><title>Cell Culture, Transfection and Cell Sorting</title><p>293T and MIN6 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (GIBCO, 31966) and INS1 in RPMI-1640 medium (Sigma R0883) according to standard procedures. Transfection of vectors, shRNA-mediated knockdown of p38&#x003b4;, and siRNA against PKD1 in different cell lines is explained in detail in the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec4.5"><title>Immunoprecipitation and Western Blotting</title><p>Transfected 293T were lysed in lysis buffer for 10 min at 4&#x000b0;C. After centrifugation at 13,000 rpm for 10 min, protein concentrations were measured in the lysate. One milligram of extract was incubated with the primary antibody (1:500) overnight at 4&#x000b0;C, followed by addition of 25 &#x003bc;l of Protein A/G Plus (Santa Cruz Biotechnology). Immobilized proteins were washed three times and analyzed by SDS-PAGE. For the experiment in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A, INS1 cells were stably transfected with a plasmid carrying <italic>HA-p38&#x003b4;<sup>F324S</sup></italic> or the relative empty control, lysed, and incubated with anti-HA antibody bound to agarose beads for 2 hr at 4&#x000b0;C. Immunoprecipitates were washed three times and analyzed by western blotting. Western blotting was performed according to standard procedures (for antibodies, see the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>).</p></sec><sec id="sec4.6"><title>In Vitro Kinase Assay</title><p>For the experiment in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B and <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>D, fully recombinant bacterial (Sigma) or Sf9 cell-derived (Cell Signaling Technology) GST-tagged PKD1, respectively, were subjected to an in&#x000a0;vitro kinase assay with recombinant GST-tagged <italic>p38&#x003b4;</italic>. For the experiment in <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>A, 293T cells were transfected with a plasmid carrying HA-tagged WT or constitutively active <italic>p38&#x003b4;</italic> isoforms (D176A and F324S), lysed, and incubated with anti-HA antibody bound to agarose beads for 2 hr at 4&#x000b0;C. Immunoprecipitates were washed and incubated for 30 min at 30&#x000b0;C in kinase buffer containing 20 &#x003bc;M ATP, 5 &#x003bc;Ci [&#x003b3;-<sup>32</sup>P] ATP, and 2 &#x003bc;g recombinant HIS-tagged ATF-2 (Santa Cruz Biotechnology). For the experiment in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D and <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>C, 293T cells were transfected with human GFP-tagged PKD1-WT, PKD1-KD, or phospho mutant PKD1 expression plasmids and lysed in standard lysis buffer for 10 min at 4&#x000b0;C, followed by centrifugation. The cleared lysates were incubated overnight with &#x003b1;-GFP sepharose (Amersham), washed three times, and used as substrates for recombinant GST-p38&#x003b4; in an in&#x000a0;vitro kinase assay, as described above. For the experiment in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F, immunoprecipitated human GFP-tagged PKD1-WT, GPF-PKD1-KD, or phospho mutant GPF-PKD1 were equalized and used together with CREBtide as a substrate in an in&#x000a0;vitro kinase assay. Kinase activity was measured by autoradiography caused by incorporation of phosphate into the CREBtide peptide (KRREILSRRPSYR) at 30&#x000b0;C with a final concentration of 50 &#x003bc;M [&#x003b3;-<sup>32</sup>P] ATP.</p></sec><sec id="sec4.7"><title>Immunofluorescence</title><p>Immunofluorescence (IF) for insulin (Linco) and glucagon (Linco) was performed on paraformaldehyde-fixed pancreatic sections. Relative islet area was measured as percentage of insulin-positive staining sections. Ten different sections per mouse were used. IF for giantin (Covance), anti-furin convertase (Abcam), and GM130 (BD Biosciences) were performed on methanol-acetone fixed INS1 and MIN6 cells and primary &#x003b2; cells. Islets were dispersed in single cells as described in single-cell capacitance measurements, incubated in RPMI 1640 medium containing 5 mM glucose for 2 hr in the presence or absence of the PI-PLC inhibitor U73122 (10 &#x003bc;M), the PKC inhibitor G&#x000f6;6976 (1 &#x003bc;M), or DMSO, and then spun onto poly-lysine-coated slides (700 G for 5 min).</p></sec><sec id="sec4.8"><title>TUNEL Assay</title><p>For the detection of apoptosis, TUNEL (terminal deoxynucleotide transferase-mediated dUTP nick end labeling) staining was performed on paraformaldehyde-fixed pancreatic sections according to the manufacturer's instruction (Roche). Apoptotic cells were quantified in islets area within the section. Three independent sections per mouse were used.</p></sec><sec id="sec4.9"><title>Real-Time RT-PCR</title><p>RNA was extracted with TRIzol (Invitrogen). cDNA was synthesized with the Ready-To-Go You-Prime First-Strand beads (Amersham). Primers are indicated in the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec4.10"><title>LC-MS/MS</title><p>A detailed description of the protein digest, peptide analysis with liquid chromatography-tandem mass spectrometry, and database searches is given in the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec4.11"><title>Electrophysiology and Measurement of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub></title><p>Whole-cell currents and exocytosis were recorded and analyzed with EPC-9 patch-clamp amplifiers and the software Pulse&#x0002b;Pulsefit (Heka Electronic). [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> was assessed in freshly isolated islets with a dual wavelength PTI system (PTI, Monmouth, NJ) fitted to an inverted microscope (for details, see the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>).</p></sec><sec id="sec4.12"><title>Statistical Analyses</title><p>Statistical significance was calculated with an ANOVA with post hoc Tukey's test and student's unpaired t test. Significance was accepted at the level of p &#x0003c; 0.05. For electron microscopy, statistical analyses are indicated in the <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec></sec><sec id="app1" sec-type="supplementary-material"><title>Supplemental Data</title><p>Supplemental Data include Supplemental Experimental Procedures, 15 figures, and two tables and can be found with article online at <ext-link xlink:href="http://www.cell.com/supplemental/S0092-8674(08)01493-1" ext-link-type="uri">http://www.cell.com/supplemental/S0092-8674(08)01493-1</ext-link>.</p></sec><sec id="app2" sec-type="supplementary-material"><title>Supplemental Data</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures, 15 Figures, and Two Tables</title></caption><media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Boehringer Ingelheim Pharmeaceuticals, Inc., Ridgefield, CT, for their generous financial support. We also would like to thank Markus Stoffel and Arne Ittner for numerous fruitful scientific discussions; Olga Herdzina for careful reading; Ana Cuenda for providing us with an antibody against p38&#x003b4;; David Engelberg for providing us with plasmids to express constitutive active p38&#x003b4;; Angelika Hausser and Vivek Malhotra for providing us with PKD plasmids; and Mary McFarland and Lynn Pantages-Torok for organizing mouse shipments. G.S. was supported by the Forschungskredit 2003 of the University of Zurich, the Swiss National Science Foundation (SNF) (PP00A-114856), and the Roche Research Foundation (337-2004). I.F. was supported by the Bonizzi-Theler Foundation. I.S. is a senior research associate in the M. Peter laboratory, and her work was supported by grants from the SNF and the ETHZ to M. Peter. B.B. is the recipient of a fellowship by the Boehringer Ingelheim Fonds. The Meda team is supported by grants from the Swiss National Science Foundation (310000-122430), the Juvenile Diabetes Research Foundation (1-2007-158), the European Union (FP-7 BETAIMAGE 222980), and Novo Nordisk. The R.A. team is supported by the SNF (31000-10767) and by the Competence Center for Systems Physiology and Metabolic Diseases, Zurich. Work in Oxford was funded by the Wellcome Trust and the European Union (Eurodia).</p></ack><ref-list><title>References</title><ref id="bib1"><label>Adams et&#x000a0;al., 2000</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.H.</given-names></name><name><surname>Porras</surname><given-names>A.</given-names></name><name><surname>Alonso</surname><given-names>G.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Vintersten</surname><given-names>K.</given-names></name><name><surname>Panelli</surname><given-names>S.</given-names></name><name><surname>Valladares</surname><given-names>A.</given-names></name><name><surname>Perez</surname><given-names>L.</given-names></name><name><surname>Klein</surname><given-names>R.</given-names></name><name><surname>Nebreda</surname><given-names>A.R.</given-names></name></person-group><article-title>Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development</article-title><source>Mol. Cell</source><year>2000</year><volume>6</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">10949032</pub-id></citation></ref><ref id="bib2"><label>Ammala et&#x000a0;al., 1994</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ammala</surname><given-names>C.</given-names></name><name><surname>Eliasson</surname><given-names>L.</given-names></name><name><surname>Bokvist</surname><given-names>K.</given-names></name><name><surname>Berggren</surname><given-names>P.O.</given-names></name><name><surname>Honkanen</surname><given-names>R.E.</given-names></name><name><surname>Sjoholm</surname><given-names>A.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name></person-group><article-title>Activation of protein kinases and inhibition of protein phosphatases play a central role in the regulation of exocytosis in mouse pancreatic beta cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>4343</fpage><lpage>4347</lpage><pub-id pub-id-type="pmid">8183910</pub-id></citation></ref><ref id="bib3"><label>Askari et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Askari</surname><given-names>N.</given-names></name><name><surname>Diskin</surname><given-names>R.</given-names></name><name><surname>Avitzour</surname><given-names>M.</given-names></name><name><surname>Capone</surname><given-names>R.</given-names></name><name><surname>Livnah</surname><given-names>O.</given-names></name><name><surname>Engelberg</surname><given-names>D.</given-names></name></person-group><article-title>Hyperactive variants of p38alpha induce, whereas hyperactive variants of p38gamma suppress, activating protein 1-mediated transcription</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">17088247</pub-id></citation></ref><ref id="bib4"><label>Aston-Mourney et&#x000a0;al., 2008</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aston-Mourney</surname><given-names>K.</given-names></name><name><surname>Proietto</surname><given-names>J.</given-names></name><name><surname>Morahan</surname><given-names>G.</given-names></name><name><surname>Andrikopoulos</surname><given-names>S.</given-names></name></person-group><article-title>Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>540</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">18246324</pub-id></citation></ref><ref id="bib5"><label>Bard and Malhotra, 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bard</surname><given-names>F.</given-names></name><name><surname>Malhotra</surname><given-names>V.</given-names></name></person-group><article-title>The formation of TGN-to-plasma-membrane transport carriers</article-title><source>Annu. Rev. Cell Dev. Biol.</source><year>2006</year><volume>22</volume><fpage>439</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">16824007</pub-id></citation></ref><ref id="bib6"><label>Beardmore et&#x000a0;al., 2005</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beardmore</surname><given-names>V.A.</given-names></name><name><surname>Hinton</surname><given-names>H.J.</given-names></name><name><surname>Eftychi</surname><given-names>C.</given-names></name><name><surname>Apostolaki</surname><given-names>M.</given-names></name><name><surname>Armaka</surname><given-names>M.</given-names></name><name><surname>Darragh</surname><given-names>J.</given-names></name><name><surname>McIlrath</surname><given-names>J.</given-names></name><name><surname>Carr</surname><given-names>J.M.</given-names></name><name><surname>Armit</surname><given-names>L.J.</given-names></name><name><surname>Clacher</surname><given-names>C.</given-names></name></person-group><article-title>Generation and characterization of p38{beta} (MAPK11) fene-targeted mice</article-title><source>Mol. Cell. Biol.</source><year>2005</year><volume>25</volume><fpage>10454</fpage><lpage>10464</lpage><pub-id pub-id-type="pmid">16287858</pub-id></citation></ref><ref id="bib7"><label>Biddinger and Kahn, 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biddinger</surname><given-names>S.B.</given-names></name><name><surname>Kahn</surname><given-names>C.R.</given-names></name></person-group><article-title>From mice to men: insights into the insulin resistance syndromes</article-title><source>Annu. Rev. Physiol.</source><year>2006</year><volume>68</volume><fpage>123</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">16460269</pub-id></citation></ref><ref id="bib8"><label>Bossard et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bossard</surname><given-names>C.</given-names></name><name><surname>Bresson</surname><given-names>D.</given-names></name><name><surname>Polishchuk</surname><given-names>R.S.</given-names></name><name><surname>Malhotra</surname><given-names>V.</given-names></name></person-group><article-title>Dimeric PKD regulates membrane fission to form transport carriers at the TGN</article-title><source>J.&#x000a0;Cell Biol.</source><year>2007</year><volume>179</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">18086912</pub-id></citation></ref><ref id="bib9"><label>de Alvaro et&#x000a0;al., 2004</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Alvaro</surname><given-names>C.</given-names></name><name><surname>Teruel</surname><given-names>T.</given-names></name><name><surname>Hernandez</surname><given-names>R.</given-names></name><name><surname>Lorenzo</surname><given-names>M.</given-names></name></person-group><article-title>Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>17070</fpage><lpage>17078</lpage><pub-id pub-id-type="pmid">14764603</pub-id></citation></ref><ref id="bib10"><label>Diaz Anel, 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz Anel</surname><given-names>A.M.</given-names></name></person-group><article-title>Phospholipase C beta3 is a key component in the Gbetagamma/PKCeta/PKD-mediated regulation of trans-Golgi network to plasma membrane transport</article-title><source>Biochem. J.</source><year>2007</year><volume>406</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">17492941</pub-id></citation></ref><ref id="bib11"><label>Drucker, 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>D.J.</given-names></name></person-group><article-title>The biology of incretin hormones</article-title><source>Cell Metab.</source><year>2006</year><volume>3</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">16517403</pub-id></citation></ref><ref id="bib12"><label>Efimova et&#x000a0;al., 2004</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Efimova</surname><given-names>T.</given-names></name><name><surname>Broome</surname><given-names>A.M.</given-names></name><name><surname>Eckert</surname><given-names>R.L.</given-names></name></person-group><article-title>Protein kinase Cdelta regulates keratinocyte death and survival by regulating activity and subcellular localization of a p38delta-extracellular signal-regulated kinase 1/2 complex</article-title><source>Mol. Cell. Biol.</source><year>2004</year><volume>24</volume><fpage>8167</fpage><lpage>8183</lpage><pub-id pub-id-type="pmid">15340077</pub-id></citation></ref><ref id="bib13"><label>Feijoo et&#x000a0;al., 2005</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feijoo</surname><given-names>C.</given-names></name><name><surname>Campbell</surname><given-names>D.G.</given-names></name><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name><name><surname>Cuenda</surname><given-names>A.</given-names></name></person-group><article-title>Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly</article-title><source>J. Cell Sci.</source><year>2005</year><volume>118</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">15632108</pub-id></citation></ref><ref id="bib14"><label>Fridlyand and Philipson, 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fridlyand</surname><given-names>L.E.</given-names></name><name><surname>Philipson</surname><given-names>L.H.</given-names></name></person-group><article-title>Reactive species, cellular repair and risk factors in the onset of type 2 diabetes mellitus: review and hypothesis</article-title><source>Curr Diabetes Rev.</source><year>2006</year><volume>2</volume><fpage>241</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">18220630</pub-id></citation></ref><ref id="bib15"><label>Gautam et&#x000a0;al., 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gautam</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>Hamdan</surname><given-names>F.F.</given-names></name><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.H.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Mears</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>C.</given-names></name></person-group><article-title>A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in&#x000a0;vivo</article-title><source>Cell Metab.</source><year>2006</year><volume>3</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">16753580</pub-id></citation></ref><ref id="bib16"><label>Gilon and Henquin, 2001</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilon</surname><given-names>P.</given-names></name><name><surname>Henquin</surname><given-names>J.C.</given-names></name></person-group><article-title>Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function</article-title><source>Endocr. Rev.</source><year>2001</year><volume>22</volume><fpage>565</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">11588141</pub-id></citation></ref><ref id="bib17"><label>Gopel et&#x000a0;al., 2004</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gopel</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Eliasson</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.S.</given-names></name><name><surname>Galvanovskis</surname><given-names>J.</given-names></name><name><surname>Kanno</surname><given-names>T.</given-names></name><name><surname>Salehi</surname><given-names>A.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name></person-group><article-title>Capacitance measurements of exocytosis in mouse pancreatic alpha-, beta- and delta-cells within intact islets of Langerhans</article-title><source>J. Physiol.</source><year>2004</year><volume>556</volume><fpage>711</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">14966302</pub-id></citation></ref><ref id="bib18"><label>Haxhinasto and Bishop, 2003</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haxhinasto</surname><given-names>S.A.</given-names></name><name><surname>Bishop</surname><given-names>G.A.</given-names></name></person-group><article-title>A novel interaction between protein kinase D and TNF receptor-associated factor molecules regulates B cell receptor-CD40 synergy</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>4655</fpage><lpage>4662</lpage><pub-id pub-id-type="pmid">14568940</pub-id></citation></ref><ref id="bib19"><label>Hirosumi et&#x000a0;al., 2002</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirosumi</surname><given-names>J.</given-names></name><name><surname>Tuncman</surname><given-names>G.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Gorgun</surname><given-names>C.Z.</given-names></name><name><surname>Uysal</surname><given-names>K.T.</given-names></name><name><surname>Maeda</surname><given-names>K.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name><name><surname>Hotamisligil</surname><given-names>G.S.</given-names></name></person-group><article-title>A central role for JNK in obesity and insulin resistance</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>333</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">12447443</pub-id></citation></ref><ref id="bib20"><label>Hui et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>L.</given-names></name><name><surname>Bakiri</surname><given-names>L.</given-names></name><name><surname>Mairhorfer</surname><given-names>A.</given-names></name><name><surname>Schweifer</surname><given-names>N.</given-names></name><name><surname>Haslinger</surname><given-names>C.</given-names></name><name><surname>Kenner</surname><given-names>L.</given-names></name><name><surname>Komnenovic</surname><given-names>V.</given-names></name><name><surname>Scheuch</surname><given-names>H.</given-names></name><name><surname>Beug</surname><given-names>H.</given-names></name><name><surname>Wagner</surname><given-names>E.F.</given-names></name></person-group><article-title>p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">17468757</pub-id></citation></ref><ref id="bib21"><label>Jiang et&#x000a0;al., 1997</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Gram</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>New</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Di Padova</surname><given-names>F.</given-names></name><name><surname>Ulevitch</surname><given-names>R.J.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name></person-group><article-title>Characterization of the structure and function of the&#x000a0;fourth member of p38 group mitogen-activated protein kinases, p38delta</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>30122</fpage><lpage>30128</lpage><pub-id pub-id-type="pmid">9374491</pub-id></citation></ref><ref id="bib22"><label>Kahn et&#x000a0;al., 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>S.E.</given-names></name><name><surname>Hull</surname><given-names>R.L.</given-names></name><name><surname>Utzschneider</surname><given-names>K.M.</given-names></name></person-group><article-title>Mechanisms linking obesity to insulin resistance and type 2 diabetes</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>840</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">17167471</pub-id></citation></ref><ref id="bib23"><label>Kaneto et&#x000a0;al., 2004</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaneto</surname><given-names>H.</given-names></name><name><surname>Nakatani</surname><given-names>Y.</given-names></name><name><surname>Miyatsuka</surname><given-names>T.</given-names></name><name><surname>Kawamori</surname><given-names>D.</given-names></name><name><surname>Matsuoka</surname><given-names>T.A.</given-names></name><name><surname>Matsuhisa</surname><given-names>M.</given-names></name><name><surname>Kajimoto</surname><given-names>Y.</given-names></name><name><surname>Ichijo</surname><given-names>H.</given-names></name><name><surname>Yamasaki</surname><given-names>Y.</given-names></name><name><surname>Hori</surname><given-names>M.</given-names></name></person-group><article-title>Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>1128</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">15448687</pub-id></citation></ref><ref id="bib24"><label>Kang et&#x000a0;al., 2008</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y.J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Otsuka</surname><given-names>M.</given-names></name><name><surname>Mols</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name></person-group><article-title>Macrophage deletion of p38{alpha} partially impairs lipopolysaccharide-induced cellular activation</article-title><source>J. Immunol.</source><year>2008</year><volume>180</volume><fpage>5075</fpage><lpage>5082</lpage><pub-id pub-id-type="pmid">18354233</pub-id></citation></ref><ref id="bib25"><label>Kinoshita et&#x000a0;al., 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>E.</given-names></name><name><surname>Kinoshita-Kikuta</surname><given-names>E.</given-names></name><name><surname>Takiyama</surname><given-names>K.</given-names></name><name><surname>Koike</surname><given-names>T.</given-names></name></person-group><article-title>Phosphate-binding tag, a new tool to visualize phosphorylated proteins</article-title><source>Mol. Cell. Proteomics</source><year>2006</year><volume>5</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">16340016</pub-id></citation></ref><ref id="bib26"><label>Koistinen et&#x000a0;al., 2003</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koistinen</surname><given-names>H.A.</given-names></name><name><surname>Chibalin</surname><given-names>A.V.</given-names></name><name><surname>Zierath</surname><given-names>J.R.</given-names></name></person-group><article-title>Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients</article-title><source>Diabetologia</source><year>2003</year><volume>46</volume><fpage>1324</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">12937895</pub-id></citation></ref><ref id="bib27"><label>Le May et&#x000a0;al., 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le May</surname><given-names>C.</given-names></name><name><surname>Chu</surname><given-names>K.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Ortega</surname><given-names>C.S.</given-names></name><name><surname>Simpson</surname><given-names>E.R.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name><name><surname>Tsai</surname><given-names>M.J.</given-names></name><name><surname>Mauvais-Jarvis</surname><given-names>F.</given-names></name></person-group><article-title>Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>9232</fpage><lpage>9237</lpage><pub-id pub-id-type="pmid">16754860</pub-id></citation></ref><ref id="bib28"><label>Li et&#x000a0;al., 2008</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>L.A.</given-names></name><name><surname>Townsend</surname><given-names>C.M.</given-names></name><name><surname>Evers</surname><given-names>B.M.</given-names></name></person-group><article-title>PKD1, PKD2, and their substrate Kidins220 regulate neurotensin secretion in the BON human endocrine cell line</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>2614</fpage><lpage>2621</lpage><pub-id pub-id-type="pmid">18048355</pub-id></citation></ref><ref id="bib29"><label>Li et&#x000a0;al., 2004</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>O'Connor</surname><given-names>K.L.</given-names></name><name><surname>Hellmich</surname><given-names>M.R.</given-names></name><name><surname>Greeley</surname><given-names>G.H.</given-names></name><name><surname>Townsend</surname><given-names>C.M.</given-names></name><name><surname>Evers</surname><given-names>B.M.</given-names></name></person-group><article-title>The role of protein kinase D in neurotensin secretion mediated by protein kinase C-alpha/-delta and Rho/Rho kinase</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>28466</fpage><lpage>28474</lpage><pub-id pub-id-type="pmid">15123666</pub-id></citation></ref><ref id="bib30"><label>Liljedahl et&#x000a0;al., 2001</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liljedahl</surname><given-names>M.</given-names></name><name><surname>Maeda</surname><given-names>Y.</given-names></name><name><surname>Colanzi</surname><given-names>A.</given-names></name><name><surname>Ayala</surname><given-names>I.</given-names></name><name><surname>Van Lint</surname><given-names>J.</given-names></name><name><surname>Malhotra</surname><given-names>V.</given-names></name></person-group><article-title>Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>409</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">11239398</pub-id></citation></ref><ref id="bib31"><label>Makeeva et&#x000a0;al., 2006</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makeeva</surname><given-names>N.</given-names></name><name><surname>Myers</surname><given-names>J.W.</given-names></name><name><surname>Welsh</surname><given-names>N.</given-names></name></person-group><article-title>Role of MKK3 and p38 MAPK in cytokine-induced death of insulin-producing cells</article-title><source>Biochem. J.</source><year>2006</year><volume>393</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">16097952</pub-id></citation></ref><ref id="bib32"><label>Mudgett et&#x000a0;al., 2000</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mudgett</surname><given-names>J.S.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Guh-Siesel</surname><given-names>L.</given-names></name><name><surname>Chartrain</surname><given-names>N.A.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Gopal</surname><given-names>S.</given-names></name><name><surname>Shen</surname><given-names>M.M.</given-names></name></person-group><article-title>Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>10454</fpage><lpage>10459</lpage><pub-id pub-id-type="pmid">10973481</pub-id></citation></ref><ref id="bib33"><label>Muoio and Newgard, 2008</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muoio</surname><given-names>D.M.</given-names></name><name><surname>Newgard</surname><given-names>C.B.</given-names></name></person-group><article-title>Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2008</year><volume>9</volume><fpage>193</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">18200017</pub-id></citation></ref><ref id="bib34"><label>O'Gorman et&#x000a0;al., 1997</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Gorman</surname><given-names>S.</given-names></name><name><surname>Dagenais</surname><given-names>N.A.</given-names></name><name><surname>Qian</surname><given-names>M.</given-names></name><name><surname>Marchuk</surname><given-names>Y.</given-names></name></person-group><article-title>Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1997</year><volume>94</volume><fpage>14602</fpage><lpage>14607</lpage><pub-id pub-id-type="pmid">9405659</pub-id></citation></ref><ref id="bib35"><label>Oancea et&#x000a0;al., 2003</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oancea</surname><given-names>E.</given-names></name><name><surname>Bezzerides</surname><given-names>V.J.</given-names></name><name><surname>Greka</surname><given-names>A.</given-names></name><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>Mechanism of persistent protein kinase D1 translocation and activation</article-title><source>Dev. Cell</source><year>2003</year><volume>4</volume><fpage>561</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12689594</pub-id></citation></ref><ref id="bib36"><label>Perdiguero et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perdiguero</surname><given-names>E.</given-names></name><name><surname>Ruiz-Bonilla</surname><given-names>V.</given-names></name><name><surname>Gresh</surname><given-names>L.</given-names></name><name><surname>Hui</surname><given-names>L.</given-names></name><name><surname>Ballestar</surname><given-names>E.</given-names></name><name><surname>Sousa-Victor</surname><given-names>P.</given-names></name><name><surname>Baeza-Raja</surname><given-names>B.</given-names></name><name><surname>Jardi</surname><given-names>M.</given-names></name><name><surname>Bosch-Comas</surname><given-names>A.</given-names></name><name><surname>Esteller</surname><given-names>M.</given-names></name></person-group><article-title>Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation</article-title><source>EMBO J.</source><year>2007</year><volume>26</volume><fpage>1245</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">17304211</pub-id></citation></ref><ref id="bib37"><label>Peter-Riesch et&#x000a0;al., 1988</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peter-Riesch</surname><given-names>B.</given-names></name><name><surname>Fathi</surname><given-names>M.</given-names></name><name><surname>Schlegel</surname><given-names>W.</given-names></name><name><surname>Wollheim</surname><given-names>C.B.</given-names></name></person-group><article-title>Glucose and carbachol generate 1,2-diacylglycerols by different mechanisms in pancreatic islets</article-title><source>J. Clin. Invest.</source><year>1988</year><volume>81</volume><fpage>1154</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">2832445</pub-id></citation></ref><ref id="bib38"><label>Storz and Toker, 2003</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storz</surname><given-names>P.</given-names></name><name><surname>Toker</surname><given-names>A.</given-names></name></person-group><article-title>Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway</article-title><source>EMBO J.</source><year>2003</year><volume>22</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12505989</pub-id></citation></ref><ref id="bib39"><label>Tamura et&#x000a0;al., 2000</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Sudo</surname><given-names>T.</given-names></name><name><surname>Senftleben</surname><given-names>U.</given-names></name><name><surname>Dadak</surname><given-names>A.M.</given-names></name><name><surname>Johnson</surname><given-names>R.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">10943842</pub-id></citation></ref><ref id="bib40"><label>Thore et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thore</surname><given-names>S.</given-names></name><name><surname>Wuttke</surname><given-names>A.</given-names></name><name><surname>Tengholm</surname><given-names>A.</given-names></name></person-group><article-title>Rapid turnover of phosphatidylinositol-4,5-bisphosphate in insulin-secreting cells mediated by Ca2&#x0002b; and the ATP-to-ADP ratio</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>818</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">17327453</pub-id></citation></ref><ref id="bib41"><label>Ventura et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>J.J.</given-names></name><name><surname>Tenbaum</surname><given-names>S.</given-names></name><name><surname>Perdiguero</surname><given-names>E.</given-names></name><name><surname>Huth</surname><given-names>M.</given-names></name><name><surname>Guerra</surname><given-names>C.</given-names></name><name><surname>Barbacid</surname><given-names>M.</given-names></name><name><surname>Pasparakis</surname><given-names>M.</given-names></name><name><surname>Nebreda</surname><given-names>A.R.</given-names></name></person-group><article-title>p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>750</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">17468755</pub-id></citation></ref><ref id="bib42"><label>Vertommen et&#x000a0;al., 2000</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vertommen</surname><given-names>D.</given-names></name><name><surname>Rider</surname><given-names>M.</given-names></name><name><surname>Ni</surname><given-names>Y.</given-names></name><name><surname>Waelkens</surname><given-names>E.</given-names></name><name><surname>Merlevede</surname><given-names>W.</given-names></name><name><surname>Vandenheede</surname><given-names>J.R.</given-names></name><name><surname>Van Lint</surname><given-names>J.</given-names></name></person-group><article-title>Regulation of protein kinase D by multisite phosphorylation. Identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>19567</fpage><lpage>19576</lpage><pub-id pub-id-type="pmid">10867018</pub-id></citation></ref><ref id="bib43"><label>von Herrath et&#x000a0;al., 2007</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Herrath</surname><given-names>M.</given-names></name><name><surname>Sanda</surname><given-names>S.</given-names></name><name><surname>Herold</surname><given-names>K.</given-names></name></person-group><article-title>Type 1 diabetes as a relapsing-remitting disease?</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>988</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">17982429</pub-id></citation></ref><ref id="bib44"><label>Wellen and Hotamisligil, 2005</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wellen</surname><given-names>K.E.</given-names></name><name><surname>Hotamisligil</surname><given-names>G.S.</given-names></name></person-group><article-title>Inflammation, stress, and diabetes</article-title><source>J. Clin. Invest.</source><year>2005</year><volume>115</volume><fpage>1111</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">15864338</pub-id></citation></ref><ref id="bib45"><label>Wiedenkeller and Sharp, 1983</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiedenkeller</surname><given-names>D.E.</given-names></name><name><surname>Sharp</surname><given-names>G.W.</given-names></name></person-group><article-title>Effects of forskolin on insulin release and cyclic AMP content in rat pancreatic islets</article-title><source>Endocrinology</source><year>1983</year><volume>113</volume><fpage>2311</fpage><lpage>2313</lpage><pub-id pub-id-type="pmid">6315349</pub-id></citation></ref><ref id="bib46"><label>Zhang et&#x000a0;al., 2005</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Storz</surname><given-names>P.</given-names></name><name><surname>Min</surname><given-names>W.</given-names></name></person-group><article-title>Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>19036</fpage><lpage>19044</lpage><pub-id pub-id-type="pmid">15755722</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Mice Lacking <italic>p38&#x003b4;</italic> Show Improved Glucose Tolerance and Enhanced Insulin Secretion</p><p>(A) Western blotting revealed expression of p38&#x003b4; in wild-type (&#x0002b;/&#x0002b;) pancreas but not in liver (Li), skeletal muscle (Sk), and white (Wa) and brown (Ba) adipose tissue compared to tissues from <italic>p38&#x003b4;</italic> null (&#x00394;/&#x00394;) mice. Coomassie blue staining was used to confirm equal loading.</p><p>(B) Glucose tolerance test (GTT) in mice with the indicated genotypes (<sup>&#x02217;</sup>p &#x0003c; 0.05, <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.01).</p><p>(C) Parallel measurements of serum insulin during the GTT in mice with the indicated genotypes (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(D) Insulin release in response to indicated stimuli (Glc, glucose; KCl, potassium chloride; tolb., tolbutamide) in isolated islets with the indicated genotypes (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(E) Glucagon secretion in response to 2.8 mM and 16.7 mM glucose in islets isolated with the indicated genotypes (ns, not significant).</p><p>All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Enhancement of Exocytosis in <italic>p38&#x003b4;</italic>-Deficient Pancreatic &#x003b2; Cells Occurs Downstream of Calcium Influx</p><p>(A) A train of ten successive 500 ms depolarizations from &#x02212;70 to 0 mV increased capacitance (in femtofarad [fF]) in pancreatic &#x003b2; cells with the indicated genotypes (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(B) Average cumulative increase of capacitance (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(C) Changes in cell capacitance (C<sub>m</sub>) when exocytosis was elicited by intracellular application of 1.5 &#x003bc;M free [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> via the recording electrode capacitance in pancreatic &#x003b2; cells with the indicated genotypes. Values have been normalized to the resting cell capacitance (C<sub>m,0</sub>), which was 4.6 &#x000b1; 0.4 pF (n &#x0003d; 8) and 4.6 &#x000b1; 0.2 pF (n &#x0003d; 16) in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> and <italic>p38&#x003b4;</italic><sup>&#x0002b;/&#x0002b;</sup> cells, respectively. Data are presented as the mean values (central lines) and &#x000b1; SEM (shaded areas).</p><p>(D) Steady-state average rate of capacitance change (in fF/s) for cells measured over a 60 s period (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>p38&#x003b4; Interacts with PKD1 and Phosphorylates It at Ser 397 and 401</p><p>(A) Western blot with indicated immunoprecipitates (IP) and whole-cell extracts (WCE) from INS1 cells stably transfected with indicated constructs confirms physical interaction with endogenous PKD1 (<sup>&#x02217;</sup>unspecific band).</p><p>(B) In&#x000a0;vitro kinase assay with and without recombinant p38&#x003b4; and recombinant <italic>E. coli</italic>-derived GST-tagged PKD1 in the presence and absence of the PKC inhibitor G&#x000f6;6976.</p><p>(C) Sequence alignment of the region around S403-407 of mouse PKD1, PKD3, and PKD2, as well as human and rat PKD1. Conserved residues (S403-407 in mPKD1, S397-401 in hPKD1) are indicated by rectangles.</p><p>(D) In&#x000a0;vitro kinase assay with recombinant p38&#x003b4; and indicated immunoprecipitated proteins. Quantification of autoradiography with corresponding bars positioned under bands (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(E) In&#x000a0;vitro kinase assay with indicated immunoprecipitated proteins using CREBtide as a substrate. CREBtide was spotted, while immunopreciptates were tested for equal loading by western blotting. Quantification of radiography using a scintillation counter with corresponding bars positioned under spots (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Increased Activity of PKD Leads to Altered Golgi Organization in <italic>p38&#x003b4;</italic>-Deficient &#x003b2; Cells</p><p>(A) Activity of protein kinase D (PKD) was determined by western blotting with an antibody against the activatory phosphorylation sites (serines 744 and 748) (BG, basal glucose and SG, stimulatory glucose levels). Immunoblotting with an antibody against Actin was used to determine equal loading of phopho-PKD and total PKD1 blots.</p><p>(B) Immunofluorescence with antibodies against giantin (red) in pancreatic &#x003b2; cells with the indicated genotypes.</p><p>(C) Immunofluorescence with antibodies against giantin (red) in INS1 cells stably expressing HA or HA-p38&#x003b4;<sup>F324S</sup> cultured in the presence of stimulatory glucose. Expression of p38&#x003b4;<sup>F324S</sup> led to formation of tubular protrusions from the Golgi complex (arrows).</p><p>(B and C) Dashed boxes outline the areas that were magnified. Nuclear DNA was stained with DAPI (blue). Scale bars represent 10 &#x003bc;m.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Restoration of Insulin Secretion in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> Islets and Glucose Tolerance in <italic>p38&#x003b4;</italic><sup>&#x00394;/&#x00394;</sup> Mice by Pharmacological Inhibition of PKD</p><p>(A) Immunofluorescence using antibodies against giantin (red) in pancreatic &#x003b2; cells with the indicated genotypes exposed to G&#x000f6;6976 (Go) or U73122 (U) as indicated. Nuclear DNA was stained with DAPI (blue). Dashed boxes outline the areas that have been magnified. The scale bar represents 10 &#x003bc;m.</p><p>(B) Glucose (16.7 mM)-stimulated insulin secretion from islets with the indicated genotypes exposed to DMSO, U73122, and G&#x000f6;6976 (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(C) Glucose tolerance test (GTT) in mice with the indicated genotypes treated with DMSO or U73122 as indicated (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>p38&#x003b4; Suppresses PKD-Mediated Stimulated Insulin Secretion</p><p>(A) Western blot to determine the activity of protein kinase D (PKD) in INS1 cells in response to indicated stimuli using an antibody against the activatory phosphorylation sites (serines 744 and 748) (<sup>&#x02217;</sup>unspecific band).</p><p>(B) SDS-PAGE with polyacrylamide-bound Mn<sup>2&#x0002b;</sup>-Phos-tag to measure the activity of p38&#x003b4; in nonstarved INS-1 cells in response to carbachol. Phosphorylated p38&#x003b4; (P-p38&#x003b4;) migrated slower than unmodified p38&#x003b4;.</p><p>(C) Western blot to determine the activity of protein kinase D (PKD) in INS1 cells stably transfected with indicated constructs in response to carbachol (<sup>&#x02217;</sup>unspecific band).</p><p>(D) Insulin secretion from INS1 cells stably expressing HA or HA-p38&#x003b4;<sup>F324S</sup> in response to carbachol under basal and stimulatory glucose levels (<sup>&#x02217;</sup>p &#x0003c; 0.05 and <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; ns, not significant).</p><p>(E) Insulin secretion in response to basal and stimulatory glucose from MIN6 cells stably expressing shRNA against p38&#x003b4; or a control vector with simultaneous siRNA-mediated knockdown of PKD1 or transfection of a scrambled siRNA (<sup>&#x02217;</sup>p &#x0003c; 0.05, <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.01, and <sup>&#x02217;&#x02217;&#x02217;</sup>p &#x0003c; 0.001; ns, not significant).</p><p>(F) Insulin secretion in response to basal and stimulatory glucose from INS1 cells stably expressing GFP, GFP-tagged WT, and mutated forms of PKD (<sup>&#x02217;</sup>p &#x0003c; 0.05 and <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.01).</p><p>(D&#x02013;F) All experiments were performed three times independently. All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr6"/></fig><fig id="fig7"><label>Figure&#x000a0;7</label><caption><p><italic>p38&#x003b4;</italic> Deficiency Protects Mice from Diabetes</p><p>(A) Blood insulin levels in fasted mice with the indicated genotypes fed a high-fat diet (HF) or a normal diet (ND) after 12 weeks (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(B) Glucose tolerance test (GTT) in mice with the indicated genotypes fed a high-fat diet (HF) or a normal diet (ND) (<sup>&#x02217;</sup>p &#x0003c; 0.05, <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.01, and <sup>&#x02217;&#x02217;&#x02217;</sup>p &#x0003c; 0.001).</p><p>(C) Blood glucose levels in mice with the indicated genotypes treated with STZ and DMSO or U73122 (<sup>&#x02217;</sup>p &#x0003c; 0.05).</p><p>(D) Blood insulin levels and (E) total pancreatic insulin content in mice with the indicated genotypes treated with DMSO or U73122 8 days after STZ injections.</p><p>(F) TUNEL stain of islets of mice with the indicated genotypes treated with STZ and DMSO or U73122 and of mice without treatment (w/o treatment).</p><p>(G) Quantification of TUNEL-positive cells in relation to islet area (<sup>&#x02217;</sup>p &#x0003c; 0.05; ns, not significant).</p><p>(H) Model: Acetylcholine (Ach)- and glucose (Glc)- induced pathways leading to increased PKD activity are indicated (M3 R, muscarinic receptor subtype M3; GLUT2, glucose transporter 2; DAG, Diacylglycerol; PLC, phospholipase C). PKD activation leads to insulin secretion and promotes &#x003b2; cell survival. In diabetes, oxidative stress-induced activation of p38&#x003b4; might interfere with PKD-mediated signaling, leading to impaired pancreatic &#x003b2; cell function.</p><p>All error bars indicate &#x000b1; SEM.</p></caption><graphic xlink:href="gr7"/></fig></floats-wrap></article> 